Navigation Links
Arsenic-based therapy shown to help eradicate leukemia-initiating cells
Date:5/12/2008

BOSTON -- In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the diseases reemergence.

The secret to the survival abilities of these cells has been unclear. But in a paradoxical discovery, a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has found that a tumor suppressor protein known as PML appears to be the factor that enables LICs to maintain their quiescence the inert state that protects them from being destroyed by cancer therapies and suggests that inhibition of PML is a promising target for new therapeutics.

Their findings, which appear in todays advance on-line issue of the journal Nature, additionally demonstrate that PML can be degraded with an arsenic-based agent used in traditional Chinese medicine. Importantly, when combined with chemotherapy, the arsenic-based therapy -- already proven safe and non-toxic in clinical trials -- can successfully treat chronic myeloid leukemia.

Leukemia initiating cells share many properties of normal hematopoetic stem cells, explains senior author Pier Paolo Pandolfi, MD, PhD, Director of the Cancer Genetics Program in BIDMCs Cancer Center and Professor of Medicine and of Pathology at Harvard Medical School. They are pluripotent, they readily replicate and they can indefinitely remain in a dormant state of quiescence.

Consequently, while the majority of leukemic cells are vulnerable to any cancer therapies including chemotherapy and targeted cancer treatments that destroy cells during active DNA replication, LICs, with their unique quiescent properties, resemble an automobile with an endless supply of fuel and a sturdy set of brakes: They sit quietly idling in place, waiting to reinitiate malignancy after a period of remission.

Pandolfis laboratory has been working to develop new therapeutic approaches to target LICs and thereby treat chronic myeloid leukemia (CML), one of the most extensively investigated of stem cell disorders. CML is typically treated with the targeted therapy imatinib (Gleevec), a tyrosine kinase inhibitor.

Gleevec does dramatically improve prognosis of CML patients, notes Pandolfi. But, unfortunately, Gleevec is not curative in most cases. Because it targets only dividing cells, the pool of quiescent LICs are able to remain intact. As a result, when Gleevec therapy is discontinued, the cancer almost inevitably relapses.

The investigators set out to analyze expression of PML, a tumor suppressor protein that controls fundamental processes such as apoptosis, cellular proliferation and senescence. PML is commonly associated with acute promyelocytic leukemia (APL), in which it leads to the formation of a fusion protein that blocks cell differentiation.

After ascertaining that PML was highly expressed in the LICs of a CML mouse model, Pandolfis team also determined that PML is highly expressed in blasts from CML patients and that low PML levels corresponded with patients increased response to therapy and overall survival rates.

We then analyzed LIC function in the absence of PML and revealed that PML has an indispensable role in maintaining LIC quiescence, he adds. As a result, PML-deficient LICs grow exhausted over time, becoming incapable of generating CML in the transplanted animals.

Lastly, the investigators examined the impact of As2O3, an arsenic-based therapy that targets PML for degradation and is currently used for the treatment of acute promyelocytic leukemia. As predicted, inhibition of PML by As2O3 successfully disrupted LICs, increasing the efficacy of the anti-cancer therapy by sensitizing the LICs to pro-apoptopic stimuli.

Its actually a very simple concept, says Pandolfi. Ninety percent of existing cancer treatments are antiproliferative agents they target the pool of proliferative cells, leaving behind the dormant LICs.

But in determining that PML serves to guard the LICs that have been left behind, we also discovered that if we knock out PML [through pharmacologic means], the LICs will lose their braking abilities and run out of gas, thereby commiting the fatal error of proliferation -- and exposing themselves to the deadly effects of cancer therapies.

Pandolfis laboratory is now trying to determine whether PML exerts a similar role in the stem cells of other tissues, as well as in the cancer initiating cells of solid tumors.

If this turn out to be the case, he adds, the transient use of As2O3 may represent a more global strategy to target CICs in other forms of cancer.


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. FDA Says, Wait To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy
2. Skin flaps deliver cancer-fighting therapy, ASPS study reveals
3. UAB first in US to offer speedier precise cancer radiotherapy
4. Virtual Reality Therapy May Help PTSD Patients
5. Kidney disease worsens in a fourth of African-Americans despite therapy for hypertension
6. Leveraging CVIS Integration to Automate Anticoagulation Therapy Webinar
7. New OPAL Therapy presents simple, cost-effective method of treating HIV infection
8. Promising early evidence of the superior benefits of drug therapy for diabetic eye disease
9. American Humane Forms Human-Animal Bond Division, Including Animal-Assisted Therapy, Humane Ed and Pets & Womens Shelters
10. Immune-Boosting Lung Cancer Therapy Shows Promise
11. Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... on the world stage this week. A group of researchers and leaders from ... the Progress of Regenerative Medicine and Its Cultural Impact ” and receive the ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... accessories, is proud to partner with AquaShieldUSA, the country's oldest waterproof cast ... clinic and medical supply stores, the largest selection of daily, night, weatherproof and ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... the open availability of a new CDISC standard, Clinical Trial Registry (CTR) ... trials. This innovative standard will make it possible to build applications that ...
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity ... Tobacco-Free Kids, a leading force in the fight to reduce tobacco use and ... policies that can help reduce tobacco use. The initiative brings together two organizations ...
(Date:4/28/2016)... ... 28, 2016 , ... In 2011, TIME magazine named Herr the “Leader of ... technology that marries human physiology with electromechanics. He continues that work as Director of ... of BionX , a leader in the field of prosthetic devices. , After ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...  The blood testing market in China ... Information and The Freedonia Group in a recent report.  ... The healthcare research firm said that China ... stations and in improving testing at the provincial level.  ... Blood Testing Market in China , which ...
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
Breaking Medicine Technology: